

ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF) Systemic Sclerosis With Lung Involvement

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Trial Status
Recruiting

Trial Runs In
17 Countries

Trial Identifier
NCT05785624 2022-502828-42
GB44496

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT05785624 2022-502828-42 GB44496
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 85 Years

Healthy Volunteers
No
